Detalles de la búsqueda
1.
Response to first-line pembrolizumab in metastatic KRAS-mutated non-small-cell lung cancer.
Future Oncol
; 20(7): 373-380, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38445372
2.
Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer.
Cancer Immunol Immunother
; 68(9): 1537-1545, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31482306
3.
Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review.
Future Oncol
; 15(9): 989-994, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30681378
4.
Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer.
Future Oncol
; 15(33): 3775-3782, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31709807
5.
Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors.
Eur J Nucl Med Mol Imaging
; 44(13): 2310-2325, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28815334
6.
Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.
Eur J Nucl Med Mol Imaging
; 43(11): 1954-61, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27251642
7.
Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography.
Am J Respir Crit Care Med
; 191(10): 1166-75, 2015 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25760561
8.
Retreatment with Immune Checkpoint Inhibitors in the New Scenario of Immunotherapy in Non-Small Cell Lung Cancer.
Cancers (Basel)
; 16(9)2024 Apr 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38730635
9.
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
Eur J Cancer
; 202: 114006, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38489861
10.
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research.
Clin Lung Cancer
; 25(2): 190-195, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38262770
11.
Current treatment approaches for brain metastases in ALK/ROS1/NTRK-positive non-small-cell lung cancer.
Expert Rev Anticancer Ther
; 23(1): 29-41, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36548111
12.
The Era of Immunotherapy in Small-Cell Lung Cancer: More Shadows Than Light?
Cancers (Basel)
; 15(24)2023 Dec 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38136306
13.
Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results.
Clin Lung Cancer
; 24(5): 467-473, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37061413
14.
Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC.
Curr Probl Cancer
; 46(1): 100787, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34489119
15.
Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors.
J Clin Med
; 10(6)2021 Mar 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-33803006
16.
Prospective Validation of the Italian Alliance Against Cancer Lung Panel in Patients With Advanced Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 22(4): e637-e641, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33642178
17.
Clinical implications of MET gene copy number in lung cancer.
Future Oncol
; 6(2): 239-47, 2010 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20146583
18.
Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1.
Front Oncol
; 10: 1090, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32850315
19.
Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer.
Immunotherapy
; 12(10): 715-724, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32522052
20.
Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters.
Cancers (Basel)
; 12(6)2020 May 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-32471030